about
MYC, Metabolism, and CancerRole of MYC in B Cell Lymphomagenesis.MYC and the control of apoptosis.Therapeutic strategies to inhibit MYCB-cell receptor signaling in diffuse large B-cell lymphoma.Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma.Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas.MiR-449a Affects Epithelial Proliferation during the Pseudoglandular and Canalicular Phases of Avian and Mammal Lung Development.Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.Dynamic changes in Id3 and E-protein activity orchestrate germinal center and plasma cell development.An overview of MYC and its interactome.Socializing with MYC: cell competition in development and as a model for premalignant cancer.Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.Genome recognition by MYC.New Approaches to Target T-ALL.Recent advances in intestinal lymphomas.MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling.Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells.Interaction of Epstein-Barr virus genes with human gastric carcinoma transcriptome.Current Trends and Alternative Scenarios in EBV Research.The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects2016 WHO Classification update-What's new in lymphoid neoplasms.6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma.Challenging perspectives on the cellular origins of lymphoma.BCL-W has a fundamental role in B cell survival and lymphomagenesis.Immunohistochemical detection of inhibitor of DNA binding 3 mutational variants in mature aggressive B-cell lymphoma.EBV and human cancer.Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma.T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.CRISPR-Cas9 Genetic Analysis of Virus-Host Interactions.Id2 Collaborates with Id3 To Suppress Invariant NKT and Innate-like Tumors.IRE1α RNase-dependent lipid homeostasis promotes survival in Myc-transformed cancers.Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.Wnt Signaling and Its Impact on Mitochondrial and Cell Cycle Dynamics in Pluripotent Stem Cells.A Decision Tree Based Classifier to Analyze Human Ovarian Cancer cDNA Microarray Datasets.Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells.
P2860
Q26783555-8AB99FE3-79A2-4184-A232-803553DD03B9Q33608499-F9CCF113-1B96-4AE1-B572-215E0B8A1F2CQ33790668-52CE92EC-502F-46AC-8D08-468399F4F3BBQ34355349-491E4611-9E59-427B-B55E-FFB26C1DB959Q35218042-EB72BF52-BD8B-4D36-8479-28E6273F95BEQ35808018-25BB66D5-9B41-40CF-BFB6-DDCBEBB77379Q35881523-AD36EDC0-1CED-4A2D-A595-ACC282F4B527Q35927500-DBF9B437-0BCD-4998-B5E6-9738F7C9A5DDQ36020943-810A14B6-B70A-4602-B1C0-150EC948A331Q36143915-4ACA5F25-A588-4C52-8B73-4717411D1E60Q36949937-46D51785-8DAD-4490-99B0-1BC1AAD7095EQ37406278-8CE9CAE9-E254-47C6-9CEE-9A2AE19A275BQ37670765-589C618F-3A3F-4EF1-8527-F7E8957A67FBQ37699251-8C4B41D0-51E1-4A5F-A622-ED0CAF5541E9Q38184910-3F8987B9-BD36-4EE7-8EF9-3D992253C8A5Q38234993-C7216E25-37CD-4F08-B650-B8A711591EB1Q38339462-7C45EAED-DEB9-4EB8-BF46-298A95DE282BQ38539670-DB06C323-92B3-4C35-9D81-F392CED76968Q38722432-E10E2D7A-1793-4F06-9836-234745432F95Q38768957-61ABAA2B-ABF9-45A4-98AB-60AFD2FC54E1Q38834097-7D44C3DF-E09E-40B7-AD75-DFF07D5A632DQ39016336-18F90368-8B3B-4B1C-8311-10CC430D734BQ39221506-BF3EA3B3-A3B7-49BC-8907-A1CE1A57AEBEQ39266295-1BFEA427-155D-43A9-A55A-45D318EC2C11Q40087588-20F7E57E-1E5E-408A-BC82-46C55F889C63Q40331337-E392B263-62C5-4BDD-9085-648B4047FB2BQ40340268-B7E11FAF-11FA-4469-98CE-E8EA293566A2Q40523569-E4D754C2-6E20-4270-BA0C-48DBDAD5ABD9Q42177793-848EFF8B-6E5B-4946-A45C-4AFB2B00694AQ42397445-A9AB31EE-945B-49C2-A460-EA5F19E0B8D6Q43128039-F96EDA38-D104-46ED-9FC3-7CAF627AC549Q44607719-73911FC5-5D5B-49C2-9062-943C3412D151Q47217197-62B2BDE0-0FBF-4A48-8B8C-9D0FB3657E5DQ47547574-062D1C3B-6F71-41A2-A456-DDA7B1371ECAQ48166027-32CA65C6-0D37-41F9-8CE9-7ABC94CF6D35Q48519557-60448FE0-98AF-4FD8-9425-DCAF5D6B962CQ49789609-B219A892-38E8-422C-90E2-F672F3451786Q49798174-30186E7A-1541-4355-AFE7-978F3FE2E5F1Q50780244-D1692415-76F8-4877-843D-D42B68452F39Q52431673-6D546369-5361-4CB2-9685-7696F79BAB83
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oncogenic mechanisms in Burkitt lymphoma
@en
Oncogenic mechanisms in Burkitt lymphoma.
@nl
type
label
Oncogenic mechanisms in Burkitt lymphoma
@en
Oncogenic mechanisms in Burkitt lymphoma.
@nl
prefLabel
Oncogenic mechanisms in Burkitt lymphoma
@en
Oncogenic mechanisms in Burkitt lymphoma.
@nl
P2093
P2860
P1476
Oncogenic mechanisms in Burkitt lymphoma
@en
P2093
George Wright
Louis M Staudt
Michele Ceribelli
Roland Schmitz
Stefania Pittaluga
P2860
P356
10.1101/CSHPERSPECT.A014282
P577
2014-02-01T00:00:00Z